Evidence map›Paper›PMID 40119433›Full record

ReviewCancer cell international2025

The artificial intelligence revolution in gastric cancer management: clinical applications.

Runze Li, Jingfan Li, Yuman Wang, Xiaoyu Liu, Weichao Xu, Runxue Sun, Binqing Xue, Xinqian Zhang, Yikun Ai, Yanru Du and 1 more

Abstract readReview
In one paragraph

Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Runze Li *Hebei University of Traditional Chinese Medicine, Hebei, 050011, China.
Jingfan Li *Hebei University of Traditional Chinese Medicine, Hebei, 050011, China.
Yuman WangHebei University of Traditional Chinese Medicine, Hebei, 050011, China.
Xiaoyu LiuHebei University of Traditional Chinese Medicine, Hebei, 050011, China.
Weichao XuHebei University of Traditional Chinese Medicine, Hebei, 050011, China.
Runxue SunHebei Hospital of Traditional Chinese Medicine, Hebei, 050011, China.
Binqing XueHebei University of Traditional Chinese Medicine, Hebei, 050011, China.
Xinqian ZhangHebei University of Traditional Chinese Medicine, Hebei, 050011, China.
Yikun AiNorth China University of Science and Technology, Tanshan 063000, China.
Yanru DuHebei Hospital of Traditional Chinese Medicine, Hebei, 050011, China. zyydyr@163.com.
Jianming JiangHebei University of Traditional Chinese Medicine, Hebei, 050011, China. 2664582148@qq.com.

Funding

Hebei Province "333 Talent Project" Funding Project C20231017Hebei Provincial Administration of Traditional Chinese Medicine Project 2023019Hebei Provincial Graduate Innovation Funding Project XCXZZSS2024026Key R&D Program of Hebei Province 23377701DNational Natural Science Foundation of China 82205314Science and Technology Project of the State Administration of Traditional Chinese Medicine GZY-KJS-2023-013
6 · The paper itself

Abstract

Nowadays, gastric cancer has become a significant issue in the global cancer burden, and its impact cannot be ignored. The rapid development of artificial intelligence technology is attempting to address this situation, aiming to change the clinical management landscape of gastric cancer fundamentally. In this transformative change, machine learning and deep learning, as two core technologies, play a pivotal role, bringing unprecedented innovations and breakthroughs in the diagnosis, treatment, and prognosis evaluation of gastric cancer. This article comprehensively reviews the latest research status and application of artificial intelligence algorithms in gastric cancer, covering multiple dimensions such as image recognition, pathological analysis, personalized treatment, and prognosis risk assessment. These applications not only significantly improve the sensitivity of gastric cancer risk monitoring, the accuracy of diagnosis, and the precision of survival prognosis but also provide robust data support and a scientific basis for clinical decision-making. The integration of artificial intelligence, from optimizing the diagnosis process and enhancing diagnostic efficiency to promoting the practice of precision medicine, demonstrates its promising prospects for reshaping the treatment model of gastric cancer. Although most of the current AI-based models have not been widely used in clinical practice, with the continuous deepening and expansion of precision medicine, we have reason to believe that a new era of AI-driven gastric cancer care is approaching.

Indexed as

Artificial intelligenceDiagnosisForecastGastric cancerResearch progressTreat

Identifiers

PMID40119433
PMCPMC11929235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.